查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1970921

流感诊断市场－全球产业规模、份额、趋势、机会、预测：按检测类型、最终用户、地区和竞争格局划分，2021-2031年

Influenza Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By End user, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球流感诊断市场预计将从 2025 年的 23.2 亿美元成长到 2031 年的 34.9 亿美元，复合年增长率为 7.05%。

此领域涵盖专门的医疗设备和检测方法，例如分子检测和快速免疫检测，旨在识别呼吸道检体中的遗传物质和病毒抗原。主要成长要素包括全球季节性流感发病率的上升，以及对准确、早期检测的迫切需求，以便及时进行治疗性介入和控制感染。此外，老年人口的成长需要定期进行健康监测，以及分散式医疗环境中对快速诊断解决方案的偏好不断增长，也推动了市场扩张。根据美国疾病管制与预防中心 (CDC) 统计，在 2024-2025 年流感季，临床检查室处理了约 390 万份与流感相关的呼吸道检体，凸显了庞大的检测量，从而满足了市场需求。

市场概览
预测期 2027-2031
市场规模：2025年 23.2亿美元
市场规模：2031年 34.9亿美元
复合年增长率：2026-2031年 7.05%
成长最快的细分市场 分子诊断检测
最大的市场 北美洲

儘管成长要素强劲，但由于先进分子诊断平台的高成本，市场仍面临许多障碍，阻碍了资源匮乏地区的普及。此外，不均衡的报销机制以及低成本快速检测的灵敏度差异，往往会加剧这些经济障碍。这些限制因素可能导致临床实务中的犹豫，并阻碍成本敏感型经济体的市场渗透。

市场驱动因素

季节性流感和流行性流感病毒株的全球传播将成为市场的主要催化剂，需要大量的诊断试剂来优化患者照护并控制感染传播。病毒的持续变异以及疫情后呼吸道病原体的再次出现将加重疾病负担，因此医疗系统必须提高警觉。例如，2023-2024 年流感季的发生率显着上升。美国疾病管制与预防中心 (CDC) 在 2024 年 11 月发布的《2023-2024 年流感季总结》中报告称，美国估计有 4,000 万例流感病例、47 万例住院病例和 2.8 万例死亡病例。这种成长趋势是全球面临的挑战，也是推动市场发展的动力。根据欧洲疾病预防控制中心 (ECDC) 2024 年 11 月发布的《季节性流感 - 2023/2024 年流行病学报告》所证实，2023 年底，巡逻医疗机构的流感阳性率达到峰值 39%，推高了全球诊断耗材的消耗量。

同时，分散式医疗机构对即时临床决策的需求推动了对快速床边检测 (POC) 解决方案的激增。医疗机构正在扩大快速分子检测和综合征检测组合的应用，这些检测可在数分钟内提供准确结果，从而加快抗病毒治疗并提高患者处理效率。这种向分散式诊断的转变已获得显着的商业性成功支持。生物梅里埃公司于 2024 年 9 月发布的「2024 财年上半年」报告显示，受快速解决方案的吸引力和安装量增加的推动，BIOFIRE 呼吸道检测组合在第二季度的销售额增长了 17%。这一趋势反映了市场结构性转变，即速度、便利性和灵敏度在呼吸道感染疾病管理中变得越来越重要。

市场挑战

先进分子诊断平台的高昂成本是全球流感诊断市场成长的主要障碍，尤其是在资源匮乏的经济体。虽然分子检测的灵敏度高于快速免疫测定，但这些先进系统所需的大量资本投入和营运成本有效地阻碍了它们在许多开发中国家和分散化地区的普及。这种经济差距迫使人们继续依赖灵敏度不可靠的低成本替代方案，导致临床结果可靠性下降，医疗机构也不愿采用新技术。因此，先进诊断技术在富裕地区已趋于饱和，而庞大的潜在市场因成本限制仍未开发，导致市场扩张分散。

诊断能力的这种差距也体现在近期关于全球准备的产业数据中。 2024年7月，创新诊断基金会（FIND）发布了病原体诊断准备指数，结果显示，全球对甲型和乙型流感的准备度得分仅为56%，远低于针对SARS-CoV-2的诊断能力。这一低分錶明，全球大部分医疗基础设施缺乏有效管理所需的诊断工具，而这项缺陷直接源自于部署精准但昂贵的检测平台所带来的经济挑战。

市场趋势

随着医疗系统日益重视同时识别多种流行呼吸道病原体，多重综合症检测的广泛应用正在改变临床工作流程。这一趋势源于临床需求，即在单一高通量流程中区分甲型流感、乙型流感、呼吸道合胞病毒（RSV）和SARS-CoV-2，从而在病毒爆发高峰期优化资源分配和患者管理。监管机构对兼具效率和灵敏度的综合检测方案的支持，正在加速从单靶点检测到多重检测的转变。正如2025年2月《BioSpectrum India》报导「赛默飞世尔科技公司获得分子临床检测510(k)批准…」报道，赛默飞世尔科技公司旗下Applied Biosystems TaqPath Select Panel多重检测方案已获得FDA批准。此方案可在单一流程中检测和识别四种病毒靶标，展现了产业向整合诊断的转型。

此外，晶片实验室和微流体技术的进步透过在紧凑的自动化晶片中实现复杂的分子处理，正在巩固市场基础。这些创新将复杂的实验室通讯协定小型化，从而能够在分散式环境中以最少的操作人员参与实现精确的样品製备和扩增。这些微流体系统应用范围的快速扩大表明，基于晶片的生态系统在应对波动的诊断负荷方面具有结构性依赖性。近期营运数据已证实了这种扩充性。根据丹纳赫公司于2025年1月发布的“2024年第四季及全年财务业绩”，其采用先进微流体晶片技术的Sepid GeneXpert系统的全球安装量已超过6万套，凸显了扩充性技术在现代诊断策略中的重要性。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球流感诊断市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依检测类型（常规诊断检测、分子诊断检测）
    • 依最终用户（医院、检验实验室等）划分
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美流感诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲流感诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区流感诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲流感诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美流感诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球流感诊断市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Abbott Laboratories Limited
  • Becton, Dickinson and Company
  • Coris BioConcept
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd
  • Meridian Bioscience Inc
  • Quidel Corporation
  • Sekisui Diagnostics
  • Thermo Fisher Scientific Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 23249

The Global Influenza Diagnostics Market is projected to expand from USD 2.32 Billion in 2025 to USD 3.49 Billion by 2031, registering a CAGR of 7.05%. This sector comprises a specialized array of medical devices and tests, such as molecular assays and rapid immunoassays, engineered to identify genetic material or viral antigens in respiratory samples. Primary growth drivers include the increasing global incidence of seasonal influenza and the urgent need for precise, early detection to enable timely therapeutic intervention and outbreak control. Additionally, market expansion is bolstered by a growing geriatric demographic requiring regular health monitoring and a shifting preference toward rapid diagnostic solutions within decentralized healthcare environments. As reported by the Centers for Disease Control and Prevention, clinical laboratories processed roughly 3.9 million respiratory specimens for influenza during the 2024 to 2025 season, highlighting the significant volume of testing that sustains demand.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.32 Billion
Market Size 2031USD 3.49 Billion
CAGR 2026-20317.05%
Fastest Growing SegmentMolecular Diagnostic Assay
Largest MarketNorth America

Despite these strong growth factors, the market encounters substantial hurdles due to the high costs linked to advanced molecular diagnostic platforms, which limit their uptake in resource-constrained areas. This economic barrier is often exacerbated by uneven reimbursement frameworks and the variable sensitivity associated with lower-cost rapid tests. Such limitations can result in clinical hesitation and hinder wider market penetration in cost-sensitive economies.

Market Driver

The escalating global prevalence of both seasonal and pandemic influenza strains serves as a major market catalyst, requiring high diagnostic volumes to optimize patient care and curb transmission. The persistent mutation of viruses and the resurgence of respiratory pathogens post-pandemic have increased the disease burden, necessitating heightened vigilance from healthcare systems. For example, the 2023-2024 season saw substantial morbidity; the Centers for Disease Control and Prevention reported in November 2024 via the '2023-2024 Influenza Season Summary' that the United States experienced an estimated 40 million flu illnesses, 470,000 hospitalizations, and 28,000 deaths. This rising incidence is a global issue fueling market momentum, as confirmed by the European Centre for Disease Prevention and Control's 'Seasonal influenza - Annual Epidemiological Report for 2023/2024' from November 2024, which noted that positive influenza tests in sentinel primary care peaked at 39% in late 2023, driving global consumption of diagnostic supplies.

Concurrently, there is a surging demand for rapid Point-of-Care (POC) testing solutions, spurred by the vital need for immediate clinical decisions in decentralized locations. Healthcare providers are increasingly adopting rapid molecular assays and syndromic panels that yield accurate results in minutes, thereby facilitating timely antiviral treatment and improved patient throughput. This transition toward decentralized diagnostics is highlighted by significant commercial gains; bioMerieux's 'First-Half 2024 Results' from September 2024 indicated a 17% rise in BIOFIRE respiratory panel sales during the second quarter, driven by the appeal of rapid solutions and a growing installed base. This trend signifies a structural market shift where speed and accessibility are becoming as critical as sensitivity in the management of respiratory outbreaks.

Market Challenge

The substantial cost associated with sophisticated molecular diagnostic platforms represents a major impediment to the growth of the Global Influenza Diagnostics Market, especially within resource-limited economies. Although molecular assays offer higher sensitivity than rapid immunoassays, the considerable capital investment and operational costs required for these advanced systems effectively preclude their use in many developing nations and decentralized settings. This financial inequality necessitates a continued dependence on less expensive alternatives that frequently demonstrate variable sensitivity, resulting in unreliable clinical outcomes and provider reluctance to embrace newer technologies. Consequently, the market experiences fragmented expansion, characterized by saturation of advanced diagnostics in affluent regions while vast potential markets remain underserved due to cost constraints.

This disparity in diagnostic capacity is evident in recent industry data concerning global preparedness. In July 2024, the Foundation for Innovative New Diagnostics (FIND) released the Pathogen Diagnostic Readiness Index, which revealed a global readiness score of merely 56% for Influenza A and Influenza B, a figure that significantly lags behind the capacity built for SARS-CoV-2. This low score suggests that a substantial proportion of global healthcare infrastructure is missing the necessary diagnostic tools for effective management, a shortfall directly attributable to the economic challenges associated with implementing precise yet costly testing platforms.

Market Trends

The widespread implementation of Multiplex Syndromic Testing is transforming clinical workflows as healthcare systems increasingly value the simultaneous identification of co-circulating respiratory pathogens. This movement is fueled by the clinical requirement to differentiate between Influenza A, Influenza B, RSV, and SARS-CoV-2 within a single high-throughput process, which optimizes resource allocation and patient management during peak viral periods. The transition from single-target assays is gaining speed due to regulatory backing for comprehensive panels that provide efficiency while maintaining sensitivity. As reported by BioSpectrum India in February 2025, in the article 'Thermo Fisher announces 510(k) clearance of molecular clinical test...', Thermo Fisher Scientific secured FDA clearance for its Applied Biosystems TaqPath Select Panel, a multiplex solution engineered to detect and distinguish these four viral targets in one workflow, highlighting the industry's shift toward consolidated diagnostic methods.

Furthermore, advancements in Lab-on-a-Chip and Microfluidic Technologies are strengthening market infrastructure by facilitating complex molecular processing inside compact, automated cartridges. These innovations allow for the miniaturization of intricate laboratory protocols, enabling precise sample preparation and amplification in decentralized settings with little need for operator involvement. The rapid growth of the installed base for these microfluidic systems suggests a structural dependence on cartridge-based ecosystems to manage variable testing loads. This scalability is demonstrated by recent operational data; according to Danaher Corporation's 'Fourth Quarter and Full Year 2024 Results' from January 2025, the global installed base for their Cepheid GeneXpert system, which utilizes advanced microfluidic cartridge technology, grew to over 60,000 instruments, underscoring the vital role of scalable technology in contemporary diagnostic strategies.

Key Market Players

  • Abbott Laboratories Limited
  • Becton, Dickinson and Company
  • Coris BioConcept
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd
  • Meridian Bioscience Inc
  • Quidel Corporation
  • Sekisui Diagnostics
  • Thermo Fisher Scientific Inc

Report Scope

In this report, the Global Influenza Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Influenza Diagnostics Market, By Test Type

  • Traditional Diagnostic Test
  • Molecular Diagnostic Assay

Influenza Diagnostics Market, By End user

  • Hospital
  • Laboratories
  • Others

Influenza Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Influenza Diagnostics Market.

Available Customizations:

Global Influenza Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Influenza Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Traditional Diagnostic Test, Molecular Diagnostic Assay)
    • 5.2.2. By End user (Hospital, Laboratories, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Influenza Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By End user
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Influenza Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By End user
    • 6.3.2. Canada Influenza Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By End user
    • 6.3.3. Mexico Influenza Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By End user

7. Europe Influenza Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By End user
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Influenza Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By End user
    • 7.3.2. France Influenza Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By End user
    • 7.3.3. United Kingdom Influenza Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By End user
    • 7.3.4. Italy Influenza Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
        • 7.3.4.2.2. By End user
    • 7.3.5. Spain Influenza Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type
        • 7.3.5.2.2. By End user

8. Asia Pacific Influenza Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By End user
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Influenza Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By End user
    • 8.3.2. India Influenza Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By End user
    • 8.3.3. Japan Influenza Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By End user
    • 8.3.4. South Korea Influenza Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
        • 8.3.4.2.2. By End user
    • 8.3.5. Australia Influenza Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type
        • 8.3.5.2.2. By End user

9. Middle East & Africa Influenza Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By End user
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Influenza Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By End user
    • 9.3.2. UAE Influenza Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By End user
    • 9.3.3. South Africa Influenza Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By End user

10. South America Influenza Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By End user
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Influenza Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
        • 10.3.1.2.2. By End user
    • 10.3.2. Colombia Influenza Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
        • 10.3.2.2.2. By End user
    • 10.3.3. Argentina Influenza Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type
        • 10.3.3.2.2. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Influenza Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories Limited
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Becton, Dickinson and Company
  • 15.3. Coris BioConcept
  • 15.4. DiaSorin SpA
  • 15.5. F. Hoffmann-La Roche Ltd
  • 15.6. Meridian Bioscience Inc
  • 15.7. Quidel Corporation
  • 15.8. Sekisui Diagnostics
  • 15.9. Thermo Fisher Scientific Inc

16. Strategic Recommendations

17. About Us & Disclaimer